Chemokine Receptor-Specific Antibodies in Cancer Immunotherapy: Achievements and Challenges

Vela, María; Aris, Mariana; Llorente, Mercedes Guinea; García‐Sanz, Jose A.; Kremer, Leonor

doi:10.3389/fimmu.2015.00012

Cited by 93 publications

(83 citation statements)

References 269 publications

(168 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Therefore CCR7 may potentially serve as a novel prognostic indicator and a potential target for gastric cancer therapy. At present, clinical trials of monoclonal antibodies against CXCR4, CCR2 and CCR4 for cancer treatment are being conducted (49).…”

Section: Lymphangiogenesis and Metastasismentioning

confidence: 99%

Molecular background of the regional lymph node metastasis of gastric cancer (Review)

Zhu

Hu²,

Wei

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

Abstract. Gastric cancer (GC) is one of the deadliest types of cancer in the world. Lymph node (LN) metastasis is a complex and malignant behavior of GC, involving a sequence of biological processes, including decreased adherence to adjacent cells, extracellular matrix (ECM) degradation and lymphatic channel permeation. LN metastasis is directly associated with the treatment response, local recurrence and long-term survival of patients with GC. Therefore, the molecular mechanisms of LN metastasis in GC development require further investigation. Recently, a large number of clinical studies have focused on the molecular mechanisms and biological markers of tumor invasion and metastasis. However, few articles have broadly summarized LN metastasis in GC, and the molecular mechanisms of LN metastasis are not yet fully understood. In the present review, the molecular mechanisms of LN metastasis in GC will be discussed, including the following aspects: Cell adhesion and movement, ECM degradation, new vessel formation, and molecular pattern differences between metastatic LNs and the primary tumor. This review may lead to a better understanding of LN metastasis in GC, and the identification of new diagnostic markers.

show abstract

Section: Lymphangiogenesis and Metastasismentioning

confidence: 99%

Molecular background of the regional lymph node metastasis of gastric cancer (Review)

Zhu

Hu²,

Wei

et al. 2018

Oncol Lett

View full text Add to dashboard Cite

show abstract

“…95 ). Preclinical development of novel CXCR4 antagonists is currently in progression [96][97][98][99][100][101][102] . However, it must be kept in mind that CXCR4 plays a critical role in embryogenesis, homeo-stasis, and inflammation in the fetus.…”

Section: Resultsmentioning

confidence: 99%

Chemokines in tumor proximal fluids

Kotyza¹

2017

BIOMED PAP

View full text Add to dashboard Cite

Chemokines are chemotactic cytokines produced by leukocytes and other types of cells including tumor cells. Their action is determined by the expression of cognate receptors and subsequent signaling in target cells, followed by the modulation of cytoskeletal proteins and the induction of other responses. In tumors, chemokines produced by neoplastic/stroma cells control the leukocyte infiltrate influencing tumor growth and progression. Tumor cells also express functional chemokine receptors responding to chemokine signals, promoting cell survival, proliferation and metastasis formation. Chemokines may be detected in serum of cancer patients, but due to the paracrine nature of these molecules, more significant concentrations are found in the tumor adjacent, non-vascular fluids, collectively called tumor proximal fluids. This review summarizes the expression of CC and CXC chemokines in these fluids, namely in interstitial fluid, pleural, ascitic, and cyst fluids, but also in urine, saliva, cerebrospinal fluid, cervical secretions and bronchoalveolar lavage fluid. Most comparative clinical studies reveal increased chemokine levels in high-grade tumor proximal fluids rather than in low-grade tumors and benign conditions, indicating shorter survival periods. The data confirm peritumoral fluid chemokines as sensitive diagnostic and prognostic markers, as well as offer support for chemokines and their receptors as potential targets for antitumor therapy.

show abstract

“…CCR4 is expressed on multiple T cell subsets and has been implicated in the pathology of inflammatory diseases and cancer. CCR4 is expressed/overexpressed on approximately 40 % of CTCL and PTCL-NOS cells and on most cells in ATL [16][17][18][19]. MOG targets CCR4 but does not affect receptor signaling and is the first of a new generation of glycoengineered antibodies which have gone to clinical trial.…”

Section: Mogamulizumabmentioning

confidence: 99%

Targets, Toxins, and T Cells—a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas

Hebb

Kohrt

2015

Curr Hematol Malig Rep

View full text Add to dashboard Cite

The peripheral T cell lymphomas (PTCLs) are a heterogeneous group of neoplasms for which standardized treatment approaches remain elusive. A number of new therapeutic agents have become available, of which monoclonal antibodies (MAbs) represent a powerful tool for targeted treatment of PTCLs. Therapeutic MAbs vary in their structure, targets, and mechanisms of action. Common mechanisms of action include antibody-dependent cell-mediated cytotoxicity, complement-dependent cytotoxicity, direct apoptosis, blocking of receptors or signaling pathways, delivery of cytotoxic agents to tumor cells, and binding to and blocking biologically active molecules. This review will focus on recent published evidence for the various MAbs used in the treatment of PTCLs. The results overall have been very promising, and the future will see more trials with these antibodies alone and in various therapy combinations, as well as newer ones with novel modifications, conjugates, and targets.

show abstract

Chemokine Receptor-Specific Antibodies in Cancer Immunotherapy: Achievements and Challenges

Cited by 93 publications

References 269 publications

Molecular background of the regional lymph node metastasis of gastric cancer (Review)

Molecular background of the regional lymph node metastasis of gastric cancer (Review)

Chemokines in tumor proximal fluids

Targets, Toxins, and T Cells—a Review of New Monoclonal Antibodies in the Treatment of Peripheral T Cell Lymphomas

Contact Info

Product

Resources

About